MedTrace Logo

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

NCT06346509 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2026-04-20

No results posted yet for this study

Summary

A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.

Conditions

  • Healthy Adult Participants

Interventions

DRUG

PORT-77

Healthy adult participants will receive PORT 77.

DRUG

Placebo

Healthy adult participants will receive matching placebo.

Sponsors & Collaborators

  • Portal Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Portal Therapeutics, Chief Medical Officer · Portal Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-08
Primary Completion
2025-12-27
Completion
2026-01-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06346509 on ClinicalTrials.gov